Acute Lymphoblastic Leukemia Treatment Market: By disease type (Acute B-lymphoblastic Leukemia, Acute T-lymphoblastic Leukemia), treatment type ( Chemotherapy ( Corticosteroids, Colony-stimulating Factors, Tyrosine Kinase Inhibitors, Others), Immunotherapy, Others)), route of administration ( Oral, Parenteral), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography.

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Acute lymphoblastic leukemia or acute lymphocytic leukemia is a type of leukemia occurs due to the accumulation and overproduction of cancerous white blood cells known as lymphoblasts in the bone marrow. It may spread to other body organs such as liver, spleen, lymph nodes, and central nervous system among others. It mostly occurs in children and sometimes in children with 2-5 years of age and rarely occurs in old age population. Common signs and symptoms associated with acute lymphoblastic leukemia include fatigue, fever, frequent infections, bruising, weight loss, joint pains, and swollen lymph glands among others. It can be diagnosed by bone marrow test, blood test, ultrasound, MRI, and CT scans among others. Acute lymphoblastic leukemia treatment market is growing at lucrative rate owing to increase in the prevalence of acute lymphoblastic leukemia prevalence in developing countries due to genetic factors. The rise in R&D activities for the innovation of newer chemotherapy and immunotherapy molecules is anticipated to fuel the market. Moreover, acquisitions and mergers, collaborations, and product launchings are the key strategies followed by the companies for dominating the acute lymphoblastic leukemia treatment industry. For instance, In April 2014, Rare Disease Therapeutics, Inc. received FDA approval for Purixan oral suspension, used in the treatment of acute lymphoblastic leukemia. Moreover, in September 2015, Baxter International Inc. acquired Oncaspar product portfolio from the Sigma-Tau Finanziaria S.p.A. for strengthening its acute lymphoblastic leukemia portfolio.

Global Acute Lymphoblastic Leukemia Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

x%

Largest Market

Europe

Fastest Growing Market

North-America
Acute Lymphoblastic Leukemia Treatment Market Dynamics

Increase in the incidence of acute lymphoblastic leukemia, rise in the R&D activities for the innovation of novel therapies, growing in healthcare expenditure, and advancement in molecular biology and pharmacology for development of novel drugs are anticipated to fuel the market. In addition, rise in awareness programs and increase in healthcare expenditure are expected propel the growth of the market over the forecast period. However, stringent regulatory policies, high cost of treatment, adverse effects associated with the treatment, and complications with chemotherapy are expected to hinder the growth of the market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Acute Lymphoblastic Leukemia Treatment Market Segmentation

disease type
  • Acute B-lymphoblastic Leukemia
  • Acute T-lymphoblastic Leukemia
  • Others
treatment type
  • Chemotherapy
    • Corticosteroids
    • Colony-stimulating Factors
    • Tyrosine Kinase Inhibitors
    • Others
  • Immunotherapy
  • Others
Route Administration
  • Oral
  • Parenteral
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1. Executive Summary 2. Global Acute Lymphoblastic Leukemia Treatment Market Introduction 2.1. Global Acute Lymphoblastic Leukemia Treatment Market – Taxonomy 2.2. Global Acute Lymphoblastic Leukemia Treatment Market –Definitions 2.2.1. Disease Type 2.2.2. Treatment Type 2.2.3. Rout of Administration 2.2.4. Distribution Channel 3. Global Acute Lymphoblastic Leukemia Treatment Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Acute Lymphoblastic Leukemia Treatment Market Dynamic Factors - Impact Analysis 3.6. Global Acute Lymphoblastic Leukemia Treatment Market – Competition Landscape 3.7. Epidemiology 4. Global Acute Lymphoblastic Leukemia Treatment Market Analysis,2015 - 2019 and Forecast, 2020 – 2026 4.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market OpportunityAnalysis 5. Global Acute Lymphoblastic Leukemia Treatment Market, By Disease Type, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 5.1. Acute B-lymphoblastic Leukemia 5.1.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.1.3. Market Opportunity Analysis 5.2. Acute T-lymphoblastic Leukemia 5.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.2.3. Market Opportunity Analysis 5.3. Others 5.3.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.3.3. Market Opportunity Analysis 6. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Treatment Type,2015 - 2019 and Forecast, 2019 – 2026 6.1. Chemotherapy 6.1.1. Corticosteroids 6.1.1.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.1.3. Market Opportunity Analysis 6.1.2. Colony-stimulating Factors 6.1.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.2.3. Market Opportunity Analysis 6.1.3. Tyrosine Kinase Inhibitors 6.1.3.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.3.3. Market Opportunity Analysis 6.1.4. Others 6.1.4.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.4.3. Market Opportunity Analysis 6.2. Immunotherapy 6.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.2.3. Market Opportunity Analysis 6.3. Others 6.3.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.3.3. Market Opportunity Analysis 7. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Route of Administration, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 7.1. Oral 7.1.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.1.3. Market Opportunity Analysis 7.2. Parenteral 7.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.2.3. Market Opportunity Analysis 8. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Distribution Channel, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 8.1. Hospital Pharmacies 8.1.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.1.3. Market Opportunity Analysis 8.2. Retail Pharmacies 8.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.2.3. Market Opportunity Analysis 8.3. Online Pharmacies Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 8.3.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.3.3. Market Opportunity Analysis 9. Global Acute Lymphoblastic Leukemia Treatment Market Forecast, By Region, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.1. North America 9.1.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.1.3. Market Opportunity Analysis 9.2. Europe 9.2.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.2.3. Market Opportunity Analysis 9.3. Asia-Pacific 9.3.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.3.3. Market Opportunity Analysis 9.4. Latin America 9.4.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.4.3. Market Opportunity Analysis 9.5. Middle East and Africa 9.5.1. Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 9.5.3. Market Opportunity Analysis 9.6. Global Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2020 – 2026 10. North America Acute Lymphoblastic Leukemia Treatment MarketAnalysis,2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 10.1. Disease Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 10.1.1. Acute B-lymphoblastic Leukemia 10.1.2. Acute T-lymphoblastic Leukemia 10.1.3. Others 10.2. Treatment Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.2.1. Chemotherapy 10.2.1.1. Corticosteroids 10.2.1.2. Colony-stimulating Factors 10.2.1.3. Tyrosine Kinase Inhibitors 10.2.1.4. Others 10.2.2. Immunotherapy 10.2.3. Others 10.3. Route of Administration Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.3.1. Oral 10.3.2. Parenteral 10.4. Distribution Channel Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Online Pharmacies 10.5. Country Analysis 2016 and Forecast 2020 - 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 10.5.1. U.S. 10.5.2. Canada 10.6. North America Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2020 – 2026 10.7. North America Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends 11. Europe Acute Lymphoblastic Leukemia Treatment Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 11.1. Disease Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 11.1.1. Acute B-lymphoblastic Leukemia 11.1.2. Acute T-lymphoblastic Leukemia 11.1.3. Others 11.2. Treatment Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.2.1. Chemotherapy 11.2.1.1. Corticosteroids 11.2.1.2. Colony-stimulating Factors 11.2.1.3. Tyrosine Kinase Inhibitors 11.2.1.4. Others 11.2.2. Immunotherapy 11.2.3. Others 11.3. Route of Administration Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.3.1. Oral 11.3.2. Parenteral 11.4. Distribution Channel Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Online Pharmacies 11.5. Country Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 11.5.1. Germany 11.5.2. UK 11.5.3. France 11.5.4. Spain 11.5.5. Italy 11.5.6. Russia 11.5.7. Poland 11.5.8. Rest of Europe 11.6. Europe Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2020 – 2026 11.7. Europe Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends 12. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 12.1. Disease Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 12.1.1. Acute B-lymphoblastic Leukemia 12.1.2. Acute T-lymphoblastic Leukemia 12.1.3. Others 12.2. Treatment Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.2.1. Chemotherapy 12.2.1.1. Corticosteroids 12.2.1.2. Colony-stimulating Factors 12.2.1.3. Tyrosine Kinase Inhibitors 12.2.1.4. Others 12.2.2. Immunotherapy 12.2.3. Others 12.3. Route of Administration Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.3.1. Oral 12.3.2. Parenteral 12.4. Distribution Channel Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Online Pharmacies 12.5. Country Analysis2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 12.5.1. Japan 12.5.2. China 12.5.3. India 12.5.4. ASEAN 12.5.5. Australia & New Zealand 12.5.6. Rest of Asia-Pacific 12.6. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2020 – 2026 12.7. Asia-Pacific Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends 13. Latin America Acute Lymphoblastic Leukemia Treatment Market Analysis, 2012 - 2012 - 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 13.1. Disease Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 13.1.1. Acute B-lymphoblastic Leukemia 13.1.2. Acute T-lymphoblastic Leukemia 13.1.3. Others 13.2. Treatment Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.2.1. Chemotherapy 13.2.1.1. Corticosteroids 13.2.1.2. Colony-stimulating Factors 13.2.1.3. Tyrosine Kinase Inhibitors 13.2.1.4. Others 13.2.2. Immunotherapy 13.2.3. Others 13.3. Route of Administration Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.3.1. Oral 13.3.2. Parenteral 13.4. Distribution Channel Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Online Pharmacies 13.5. Country Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Argentina 13.5.4. Venezuela 13.5.5. Rest of Latin America 13.6. Latin America Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel,and Region, 2020 – 2026 13.7. Latin America Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends 14. Middle East and Africa Acute Lymphoblastic Leukemia Treatment Market Analysis, 2015 - 2019 and Forecast, 2020 - 2026 (Revenue, USD Mn) 14.1. Disease Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) 14.1.1. Acute B-lymphoblastic Leukemia 14.1.2. Acute T-lymphoblastic Leukemia 14.1.3. Others 14.2. Treatment Type Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.2.1. Chemotherapy 14.2.1.1. Corticosteroids 14.2.1.2. Colony-stimulating Factors 14.2.1.3. Tyrosine Kinase Inhibitors 14.2.1.4. Others 14.2.2. Immunotherapy 14.2.3. Others 14.3. Route of Administration Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.3.1. Oral 14.3.2. Parenteral 14.4. Distribution Channel Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 14.4.1. Hospital Pharmacies 14.4.2. Retail Pharmacies 14.4.3. Online Pharmacies 14.5. Country Analysis 2015 - 2019 and Forecast 2020 - 2026 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 14.5.1. Gulf Cooperation Council (GCC) Countries 14.5.2. Israel 14.5.3. South Africa 14.5.4. Rest of MEA 14.6. MEA Acute Lymphoblastic Leukemia Treatment Market - Opportunity Analysis Index, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, and Region, 2020 – 2026 14.7. MEA Acute Lymphoblastic Leukemia Treatment Market Dynamics – Trends 15. Competition Landscape 15.1. Strategic Dashboard of Top Market Players 15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis) 15.2.1. Pfizer, Inc. (U.S.) 15.2.2. Sigma-Tau Pharmaceuticals, Inc. (U.S.) 15.2.3. GlaxoSmithKline plc (U.K.) 15.2.4. Genzyme Corporation (U.S.) 15.2.5. Talon Therapeutic, Inc. (U.S.) 15.2.6. Erytech Pharma (France) 15.2.7. Baxter International Inc. (U.S.) 15.2.8. Novartis AG (Switzerland) 15.2.9. Rare Disease Therapeutics, Inc. (U.S.) 16. Research Methodology 17. Key Assumptions and Acronyms
  • Pfizer, Inc. (U.S.)
  • Sigma-Tau Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Genzyme Corporation (U.S.)
  • Talon Therapeutic, Inc. (U.S.)
  • Erytech Pharma (France)
  • Baxter International Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Rare Disease Therapeutics, Inc. (U.S.)